These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 37298304)

  • 1. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
    Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I and III interferon responses in SARS-CoV-2 infection.
    Kim YM; Shin EC
    Exp Mol Med; 2021 May; 53(5):750-760. PubMed ID: 33953323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
    Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P
    Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Antiviral Immune Evasion of SARS-CoV-2.
    Beyer DK; Forero A
    J Mol Biol; 2022 Mar; 434(6):167265. PubMed ID: 34562466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
    Metz-Zumaran C; Kee C; Doldan P; Guo C; Stanifer ML; Boulant S
    J Virol; 2022 Apr; 96(7):e0170521. PubMed ID: 35262371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon antagonists encoded by SARS-CoV-2 at a glance.
    Lee JH; Koepke L; Kirchhoff F; Sparrer KMJ
    Med Microbiol Immunol; 2023 Apr; 212(2):125-131. PubMed ID: 35366686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
    Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options.
    Znaidia M; Demeret C; van der Werf S; Komarova AV
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
    Park A; Iwasaki A
    Cell Host Microbe; 2020 Jun; 27(6):870-878. PubMed ID: 32464097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Update on Innate Immune Responses during SARS-CoV-2 Infection.
    Zhang Y; Chen S; Jin Y; Ji W; Zhang W; Duan G
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways.
    Han L; Zhuang MW; Deng J; Zheng Y; Zhang J; Nan ML; Zhang XJ; Gao C; Wang PH
    J Med Virol; 2021 Sep; 93(9):5376-5389. PubMed ID: 33913550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate immune sensing of coronavirus and viral evasion strategies.
    Kasuga Y; Zhu B; Jang KJ; Yoo JS
    Exp Mol Med; 2021 May; 53(5):723-736. PubMed ID: 33953325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN-
    Anjum FR; Anam S; Abbas G; Mahmood MS; Rahman SU; Goraya MU; Abdullah RM; Luqman M; Ali A; Akram MK; Chaudhry TH
    Viral Immunol; 2021 Jun; 34(5):321-329. PubMed ID: 33181057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection.
    Chiale C; Greene TT; Zuniga EI
    Immunol Rev; 2022 Aug; 309(1):12-24. PubMed ID: 35775361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons.
    Jafarzadeh A; Nemati M; Saha B; Bansode YD; Jafarzadeh S
    Viral Immunol; 2021 Jun; 34(5):307-320. PubMed ID: 33147113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development.
    Zhao X; Chen D; Li X; Griffith L; Chang J; An P; Guo JT
    J Mol Biol; 2022 Mar; 434(6):167438. PubMed ID: 34990653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2.
    Xia H; Shi PY
    J Interferon Cytokine Res; 2020 Dec; 40(12):543-548. PubMed ID: 33337934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N7-Methylation of the Coronavirus RNA Cap Is Required for Maximal Virulence by Preventing Innate Immune Recognition.
    Pan R; Kindler E; Cao L; Zhou Y; Zhang Z; Liu Q; Ebert N; Züst R; Sun Y; Gorbalenya AE; Perlman S; Thiel V; Chen Y; Guo D
    mBio; 2022 Feb; 13(1):e0366221. PubMed ID: 35073761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2-mediated evasion strategies for antiviral interferon pathways.
    Oh SJ; Shin OS
    J Microbiol; 2022 Mar; 60(3):290-299. PubMed ID: 35122601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.